|
Until January, 2001,
President and Chief Executive Officer (CEO) of Continuum Health Partners, a
$2.2 billion hospital network in New York City. Prior to the creation of
Continuum in 1997, CEO of Beth Israel Health Care System for 20 years. Currently
President Emeritus of Continuum and Director of The Baron Edmond de
Rothschild Chemical Dependency Institute of Beth Israel Medical Center.
For the past 35 years Dr.
Newman has played a major role in planning and directing some of the largest
addiction treatment programs in the world - including the New York City Methadone
Maintenance and Ambulatory Detoxification Programs, which in the mid-‘70s
treated over 33,000 patients annually.
He has also been a strong addiction treatment advocate in Europe,
Australia and Asia. Throughout his
career he has championed the right of drug-dependent persons to treatment
access and choice of provider, and the right to be cared for under the same
conditions as apply to the management of all other chronic medical
conditions.
Graduate (with honors) from
University of Rochester (NY) School of Medicine and Dentistry, 1963. Master’s
Degree in Public Health from the University of California, Berkeley, 1969.
Professor of Epidemiology and Population Health and Professor of Psychiatry
and Behavioral Sciences, Albert Einstein College of Medicine in New
York.
|
|
Newman RG : The need to redefine « addiction. » New Eng J Med 308:1096-1098, 1983
Newman RG: Methadone Treatment
– Defining and Evaluating Success. New Eng J Med 317:447-450, 1987
Newman RG: Methadon in der
Behandlung der Drogensucht – 20 Jahre Erfahrung mit der Ersatzdroge in New
York. Deutsche Aerztezeitung 7(23):2-10, 1988
Newman RG und Täschner K-L: pro
und contra Stellungnahme. Methadon für
Drogensüchtige (Newman); Methadon und
kein Ende (Täschner). Aerzteblatt
Baden-Württemberg 5:358-362, 1989
Newman RG: La maladie de la
toxicomanie: un défi pour la clinique
et la santé publique. In, Les Traitements de Substitution pour les
Usagers de Drogues. Touzeau D et
Jacquot C (eds.), Arnette SA ; Paris, 1997, pp. 237-243
|
office@infodrog.ch | 
+41 (0)31 376 04 01